리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 375 Pages
라이선스 & 가격 (부가세 별도)
한글목차
글루카곤 유사 펩티드 1 작용제 세계 시장은 2030년까지 221억 달러에 달할 전망
2024년에 172억 달러로 추정되는 글루카곤 유사 펩티드 1 작용제 세계 시장은 2024-2030년 분석 기간에 CAGR 4.3%로 성장하여 2030년에는 221억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 엑세나타이드는 CAGR 3.7%를 기록하며 분석 기간 종료시에는 109억 달러에 달할 것으로 예측됩니다. 리라글루타이드 부문의 성장률은 분석 기간 동안 CAGR 5.3%로 추정됩니다.
미국 시장은 47억 달러로 추정, 중국은 CAGR 7.8%로 성장 예측
미국의 글루카곤 유사 펩티드 1 작용제 시장은 2024년에 47억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 45억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.8%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.8%와 3.3%로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%로 성장할 것으로 예측됩니다.
글루카곤 유사 펩티드-1(GLP-1) 작용제 세계 시장 - 주요 동향과 촉진요인 정리
GLP-1 작용제가 대사 이상 치료의 전망을 재구성하는 이유는 무엇일까?
글루카곤 유사 펩타이드-1(GLP-1) 수용체 작용제는 세계에서 가장 널리 퍼져 있는 두 가지 대사 이상 질환인 제2형 당뇨병과 비만 관리에 혁명을 일으켰습니다. 이 약물은 내인성 GLP-1 호르몬의 작용을 모방하여 포도당 의존성 인슐린 분비를 촉진하고, 글루카곤 방출을 억제하고, 위 배출을 지연시키고, 식욕을 감소시킵니다. 기존 항당뇨병제와는 달리 GLP-1 작용제는 혈당 조절과 체중 감소라는 두 가지 이점을 제공하기 때문에 더 많은 환자들에게 매력적인 약물이며, GLP-1 작용제의 역할은 혈당 조절에만 국한되지 않고 심혈관 위험 감소에 대한 임상적 근거가 축적됨에 따라 세계 치료 가이드라인에서 GLP-1 작용제의 위치는 더욱 강화되고 있습니다. 전 세계 치료 가이드라인에서 GLP-1 작용제의 위치는 더욱 확고해지고 있습니다.
GLP-1 작용제의 특징은 그 작용 기전이 제2형 당뇨병과 비만의 병태생리와 밀접한 관련이 있다는 것입니다. 이들 약제는 현재 동맥경화성 심혈관질환, 만성 신장 질환, 심부전 등의 합병증을 가진 환자에게 1차 선택약물 또는 보조요법으로 권장되고 있습니다. GLP-1 수용체 작용제는 주 1회 투여가 가능한 새로운 제형과 최근 경구용 제제의 승인으로 인해 주 1회 투여가 가능해지면서, 전 세계적으로 당뇨병과 비만, 특히 도시화되고 고령화된 인구 집단에서 당뇨병과 비만의 유병률이 증가함에 따라 대사 기능 장애와 심혈관질환의 이중적 유병률에 대응할 수 있게 되었습니다. 대사 기능 장애와 심혈관질환의 이중적 확산을 관리하기 위한 핵심 약물이 되고 있습니다.
의약품의 혁신과 제형은 어떻게 시장의 가능성을 넓히고 있는가?
GLP-1 수용체 작용제는 분자 개발 및 제제 기술 양면에서 큰 기술 혁신을 이루고 있습니다. 세마글루티드, 틸제파타이드, 틸제파타이드(듀얼 GLP-1/GIP 수용체 작용제), 듀라글루티드 등 2세대 약물은 유효성, 내약성 및 환자 순응도 측면에서 새로운 기준을 세우고 있습니다. 특히 세마글루티드는 초기 유사 약물에 비해 우수한 HbA1c 감소와 체중 감소를 보여 당뇨병(오젬픽)과 만성 체중 조절(웨고비) 적응증으로 모두 승인되었습니다. 이러한 발전은 당뇨병 환자뿐만 아니라 당뇨병 유무에 관계없이 비만 및 대사증후군 환자들에게도 치료 패러다임을 재정의하고 있습니다.
제약사들은 장기지속형 제제, 경구용 생체이용률 개선, 복합제 등에 많은 투자를 하고 있습니다. 경구용 세마글루타이드의 승인은 주사 요법에 따른 심리적, 물류적 장벽을 극복할 수 있는 큰 돌파구가 되었습니다. 또한, GLP-1 작용제와 SGLT2 억제제 또는 기저 인슐린을 통합한 병용요법은 부작용이 적고 종합적인 대사 관리를 제공하기 위해 검토되고 있으며, GLP-1, GIP, 글루카곤 수용체를 표적으로 하는 차세대 이중 작용제 및 삼중 작용제 파이프라인이 풍부하게 존재하고 있습니다. 체중감량 및 인슐린 감수성에 시너지 효과를 가져다 줄 수 있는 차세대 듀얼 및 트리플 작용제 파이프라인이 풍부합니다. 이러한 혁신으로 GLP-1 기반 치료제의 임상적 유용성과 상업적 범위가 확대되고 있습니다.
GLP-1 치료제에 대한 시장 역학 및 접근성을 재구축하고 있는 동향은?
GLP-1 작용제에 대한 강력한 수요는 의약품 공급망, 지불자 모델, 환자 참여 전략 전반에 걸쳐 구조적인 변화를 촉진하고 있습니다. 특히 비당뇨병 환자들 사이에서 급증하고 있는 체중 감소를 목적으로 한 적응증 외 수요는 일부 시장에서 세계 공급 제약과 배급 제한을 초래하고 있으며, GLP-1 작용제는 생활습관 개선 약물이라는 인식이 확산되고, 소셜 미디어, 유명인 추천, 웰빙 인플루엔자 웰빙 인플루언서들에 의해 일반 소비자의 인식이 높아지면서 소비자 행동이 재구성되고 있습니다. 이에 따라 규제 당국과 의료 시스템은 의약품의 상환 및 임상적 적격성 관련 정책을 재검토해야 할 필요성이 대두되고 있습니다.
시장 개척은 여전히 큰 과제이며, 특히 신흥 경제국에서는 GLP-1 작용제의 높은 가격으로 인해 환자 보급이 제한적일 수밖에 없습니다. 그러나 바이오시밀러의 개발과 제네릭 의약품의 경쟁으로 인해 10년 후에는 가격 역학에 영향을 미칠 것으로 예상됩니다. 또 다른 중요한 트렌드는 커넥티드 디바이스 및 모바일 건강 앱과 같은 디지털 건강 기술의 통합이며, 이는 GLP-1 치료와 결합하여 순응도 개선, 결과 모니터링 및 개인화된 개입을 제공하기 위해 결합되고 있습니다. 또한, 보험사 및 고용주들은 비만 및 당뇨병과 관련된 장기적인 의료비 절감을 목표로 하는 광범위한 질병 관리 프로그램의 일환으로 GLP-1 치료에 대한 보험 적용에 대한 관심이 높아지고 있습니다.
치료 프런티어 전체에서 GLP-1 작용제 시장의 급격한 성장의 원동력은 무엇인가?
GLP-1 작용제 시장의 성장은 의약품 혁신, 치료 적응증 확대, 의료 우선순위 변화와 직접적으로 관련된 여러 요인에 의해 주도되고 있으며, 제2형 당뇨병 및 비만 유병률 증가, 기존 치료제 대비 GLP-1 작용제의 우수한 효능 및 안전성 프로파일이 결합되어 전 세계 제1선택 약물의 채택을 촉진하고 있습니다. 과 함께 전 세계적으로 GLP-1 작용제의 1차 선택 약물로 채택이 가속화되고 있습니다. 당뇨병 유무에 관계없이 체중 조절을 위한 약품이 승인되면서 완전히 새로운 치료 영역이 열렸고, 지금까지 충분히 치료받지 못했던 방대한 세계 환자층을 개척할 수 있게 되었습니다.
또한, 세마글루티드와 틸제파타이드와 같은 약물이 심혈관계 위험 감소와 체중 감소에 성공하면서 의사들의 신뢰와 환자들의 수요가 증가하고 있습니다. 경구용 제형과 주 1회 투여 등 약물전달의 발전은 환자의 편의성과 순응도를 향상시켜 시장 침투를 더욱 촉진하고 있습니다. 차세대 이중 및 삼중 수용체 작용제 파이프라인은 특히 비알코올성 지방간염(NASH)과 같은 복잡한 대사성 질환에 대한 임상적 영향력을 더욱 확대할 수 있을 것으로 기대됩니다. 마지막으로, 결과 중심의 치료에 대한 지불자의 관심 증가와 대사성 질환에 대한 대중의 인식이 높아지면서 선진국과 신흥국의 의료 시스템에서 GLP-1 작용제들의 상환 경로와 시장 진입이 가속화되고 있습니다.
부문
약물 유형(엑세나타이드, 리라글루타이드, 릭시세나타이드, 듀라글루타이드), 투여 경로(경구, 비경구, 기타 투여 경로), 최종사용자(병원, 전문 클리닉, 기타 최종사용자)
조사 대상 기업 사례(총 39개사)
Altimmune, Inc.
Amgen Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
Crinetics Pharmaceuticals, Inc.
Eccogene Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GSK plc
Hanmi Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Novo Nordisk A/S
Oramed Pharmaceuticals Inc.
Pfizer Inc.
Sanofi S.A.
Terns Pharmaceuticals, Inc.
Veru Inc.
Viking Therapeutics, Inc.
Zealand Pharma A/S
Zydus Lifesciences Limited
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월 : 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월 : 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석:
미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국
업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Glucagon-Like Peptide 1 Agonists Market to Reach US$22.1 Billion by 2030
The global market for Glucagon-Like Peptide 1 Agonists estimated at US$17.2 Billion in the year 2024, is expected to reach US$22.1 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Exenatide, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$10.9 Billion by the end of the analysis period. Growth in the Liraglutide segment is estimated at 5.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$4.7 Billion While China is Forecast to Grow at 7.8% CAGR
The Glucagon-Like Peptide 1 Agonists market in the U.S. is estimated at US$4.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.
Why Are GLP-1 Agonists Reshaping the Landscape of Metabolic Disorder Therapies?
Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the management of type 2 diabetes and obesity, two of the world’s most pervasive metabolic disorders. These drugs mimic the action of the endogenous GLP-1 hormone, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite. Unlike traditional antidiabetic medications, GLP-1 agonists offer the dual benefits of glycemic control and weight loss, making them attractive for a broader patient population. Their role has expanded well beyond glucose management, with mounting clinical evidence demonstrating cardiovascular risk reduction, which has further solidified their place in treatment guidelines globally.
What distinguishes GLP-1 agonists is their mechanism of action that aligns closely with the pathophysiology of type 2 diabetes and obesity. These agents are now recommended as first-line or adjunct therapy for patients with comorbidities such as atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure. Their injectable nature, once considered a barrier to adoption, has been addressed by newer formulations with weekly dosing and the recent approval of oral versions. With the growing global prevalence of diabetes and obesity, particularly in urbanized and aging populations, GLP-1 receptor agonists have become central to managing the dual epidemic of metabolic dysfunction and cardiovascular disease.
How Are Drug Innovations and Formulations Expanding Market Potential?
The GLP-1 agonist landscape is undergoing significant innovation, both in molecule development and formulation technologies. Second-generation agents such as semaglutide, tirzepatide (a dual GLP-1/GIP receptor agonist), and dulaglutide are setting new benchmarks for efficacy, tolerability, and patient adherence. Semaglutide, in particular, has demonstrated superior HbA1c reduction and weight loss compared to earlier analogs, leading to its approval for both diabetes (Ozempic) and chronic weight management (Wegovy). These advances are redefining treatment paradigms not only for diabetics but also for individuals with obesity and metabolic syndrome, irrespective of their diabetic status.
Pharmaceutical companies are heavily investing in long-acting formulations, oral bioavailability improvements, and fixed-dose combination products. The approval of oral semaglutide marked a major breakthrough, addressing the psychological and logistical barriers associated with injectable therapies. Additionally, combination therapies that integrate GLP-1 agonists with SGLT2 inhibitors or basal insulin are being explored to offer comprehensive metabolic management with fewer side effects. Pipelines are rich with next-generation dual and triple agonists targeting GLP-1, GIP, and glucagon receptors, offering synergistic benefits in weight reduction and insulin sensitivity. These innovations are expanding both the clinical utility and commercial scope of GLP-1-based treatments.
What Trends Are Reshaping Market Dynamics and Access to GLP-1 Therapies?
The strong demand for GLP-1 agonists is driving structural changes across the pharmaceutical supply chain, payor models, and patient engagement strategies. One significant trend is the surging off-label demand for weight loss, especially among non-diabetic populations, which has led to global supply constraints and rationing in some markets. The growing perception of GLP-1 agonists as lifestyle-enhancing drugs-amplified by social media, celebrity endorsements, and wellness influencers-has increased public awareness and reshaped consumer behavior. This is pushing regulatory agencies and healthcare systems to revisit policies on drug reimbursement and clinical eligibility.
Market access remains a major challenge, particularly in developing economies, where the high cost of GLP-1 agonists limits patient uptake. However, biosimilar development and generic competition are expected to influence pricing dynamics by the end of the decade. Another important trend is the integration of digital health technologies, such as connected devices and mobile health apps, which are being paired with GLP-1 treatments to improve adherence, monitor outcomes, and deliver personalized interventions. Additionally, insurers and employers are showing increased interest in covering GLP-1 therapies as part of broader disease management programs aimed at reducing long-term healthcare costs linked to obesity and diabetes.
What Is Driving the Rapid Expansion of the GLP-1 Agonists Market Across Therapeutic Frontiers?
The growth in the GLP-1 agonists market is driven by several factors directly related to drug innovation, expanding therapeutic indications, and shifting healthcare priorities. The increasing prevalence of type 2 diabetes and obesity, combined with the superior efficacy and safety profile of GLP-1 agonists compared to older therapies, is accelerating first-line adoption worldwide. Regulatory approvals for weight management-independent of diabetes status-have opened an entirely new therapeutic frontier, tapping into a vast and previously underserved global patient base.
Moreover, the success of agents like semaglutide and tirzepatide in reducing cardiovascular risk and achieving substantial weight loss has strengthened physician confidence and patient demand. Advances in drug delivery, including oral formulations and once-weekly dosing, are improving patient convenience and adherence, further supporting market penetration. The pipeline of next-generation dual and triple receptor agonists promises even greater clinical impact, particularly in addressing complex metabolic diseases like non-alcoholic steatohepatitis (NASH). Finally, rising payer interest in outcome-driven therapies, coupled with growing public awareness of metabolic health, is accelerating reimbursement pathways and market access for GLP-1 agonists across both developed and emerging healthcare systems.
SCOPE OF STUDY:
The report analyzes the Glucagon-Like Peptide 1 Agonists market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Type (Exenatide, Liraglutide, Lixisenatide, Dulaglutide); Administration Route (Oral, Parenteral, Other Administration Routes); End-Use (Hospitals, Specialty Clinics, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 39 Featured) -
Altimmune, Inc.
Amgen Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
Crinetics Pharmaceuticals, Inc.
Eccogene Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GSK plc
Hanmi Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Novo Nordisk A/S
Oramed Pharmaceuticals Inc.
Pfizer Inc.
Sanofi S.A.
Terns Pharmaceuticals, Inc.
Veru Inc.
Viking Therapeutics, Inc.
Zealand Pharma A/S
Zydus Lifesciences Limited
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Glucagon-Like Peptide 1 Agonists - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Prevalence of Type 2 Diabetes Drives Widespread Adoption of GLP-1 Agonist Therapies
Surge in Obesity Rates Across Key Markets Expands Addressable Population for GLP-1-Based Weight Management Drugs
Increasing Use of GLP-1 Agonists as First-Line Therapy Spurs Market Share Shift Away from Traditional Antidiabetics
Favorable Cardiovascular Outcomes Data Strengthens the Clinical Case for Expanded Use of GLP-1 Agonists
Growing Physician Preference for Weekly and Once-Daily Dosing Options Fuels Uptake of Long-Acting Formulations
FDA Approvals for Weight Loss Indications Propel Growth in Non-Diabetic Patient Populations
Integration of GLP-1 Agonists into Obesity Care Pathways Accelerates Demand Beyond Traditional Diabetes Use
Expansion of Combination Therapies with SGLT2 Inhibitors and Insulins Enhances Therapeutic Flexibility
Increased Payer Acceptance and Reimbursement Coverage Strengthens Market Access for GLP-1 Drugs
Pipeline Innovation in Oral GLP-1 Formulations Reduces Dependence on Injectable Delivery Systems
Rising Consumer Awareness of Metabolic Health Enhances Direct-to-Patient Demand for Weight Control Solutions
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Glucagon-Like Peptide 1 Agonists Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Exenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Exenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Exenatide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Liraglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Liraglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Liraglutide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Lixisenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Lixisenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Lixisenatide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Dulaglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Dulaglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Dulaglutide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 35: USA Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Canada 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
JAPAN
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 53: Japan Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Japan 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
CHINA
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 62: China Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: China 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
EUROPE
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 71: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
FRANCE
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 83: France Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: France 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
GERMANY
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 92: Germany Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Germany 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
ITALY
TABLE 101: Italy Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Italy 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
UNITED KINGDOM
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 110: UK Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: UK 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
SPAIN
TABLE 119: Spain Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Spain 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 122: Spain Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
RUSSIA
TABLE 128: Russia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Russia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 131: Russia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
AUSTRALIA
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 158: Australia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Australia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 161: Australia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
INDIA
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 167: India Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: India Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: India 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 170: India Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 176: South Korea Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: South Korea 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 179: South Korea Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
LATIN AMERICA
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 194: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 206: Argentina Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Argentina 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 209: Argentina Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
BRAZIL
TABLE 215: Brazil Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: Brazil 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 218: Brazil Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
MEXICO
TABLE 224: Mexico Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: Mexico 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 227: Mexico Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: Rest of Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
MIDDLE EAST
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 242: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
IRAN
TABLE 254: Iran Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Iran 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 257: Iran Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
ISRAEL
TABLE 263: Israel Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Israel 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 266: Israel Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Saudi Arabia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 281: UAE Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: UAE 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 284: UAE Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: Rest of Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
AFRICA
Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 299: Africa Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Africa 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
TABLE 302: Africa Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030